Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Equity Average (2022 - 2025)

Historic Equity Average for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $50.4 million.

  • Mereo BioPharma's Equity Average fell 3334.37% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.4 million, marking a year-over-year decrease of 3334.37%. This contributed to the annual value of $55.8 million for FY2024, which is 938.5% up from last year.
  • Per Mereo BioPharma's latest filing, its Equity Average stood at $50.4 million for Q3 2025, which was down 3334.37% from $57.1 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Equity Average high stood at $103.1 million for Q2 2022, and its period low was $46.7 million during Q1 2024.
  • Its 3-year average for Equity Average is $65.6 million, with a median of $60.7 million in 2024.
  • Data for Mereo BioPharma's Equity Average shows a peak YoY increase of 2963.86% (in 2025) and a maximum YoY decrease of 3334.37% (in 2025) over the last 5 years.
  • Over the past 3 years, Mereo BioPharma's Equity Average (Quarter) stood at $69.5 million in 2022, then dropped by 3.97% to $66.8 million in 2024, then decreased by 24.52% to $50.4 million in 2025.
  • Its last three reported values are $50.4 million in Q3 2025, $57.1 million for Q2 2025, and $60.5 million during Q1 2025.